| Literature DB >> 32878114 |
Giordano Perini1,2, Valentina Palmieri1,2,3, Gabriele Ciasca1,2, Marcello D'Ascenzo1,2, Jacopo Gervasoni2,4, Aniello Primiano2,4, Monica Rinaldi5, Daniela Fioretti5, Chiara Prampolini2,6, Federica Tiberio2,6, Wanda Lattanzi2,6, Ornella Parolini2,6, Marco De Spirito1,2, Massimiliano Papi1,2.
Abstract
Recent evidence has shown that graphene quantum dots (GQDs) are capable of crossing the blood-brain barrier, the barrier that reduces cancer therapy efficacy. Here, we tested three alternative GQDs' surface chemistries on two neural lineages (glioblastoma cells and mouse cortical neurons). We showed that surface chemistry modulates GQDs' biocompatibility. When used in combination with the chemotherapeutic drug doxorubicin, GDQs exerted a synergistic effect on tumor cells, but not on neurons. This appears to be mediated by the modification of membrane permeability induced by the surface of GQDs. Our findings highlight that GQDs can be adopted as a suitable delivery and therapeutic strategy for the treatment of glioblastoma, by both directly destabilizing the cell membrane and indirectly increasing the efficacy of chemotherapeutic drugs.Entities:
Keywords: cancer treatment; glioblastoma; graphene quantum dots; nanomedicine; synergistic therapy
Mesh:
Substances:
Year: 2020 PMID: 32878114 PMCID: PMC7503375 DOI: 10.3390/ijms21176301
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Characterization of the three functionalized graphene quantum dots (GQDs). Dynamic light scattering (DLS), atomic force microscopy (AFM imaging, height distribution, fluorescence spectra and Fourier transform infrared spectroscopy (FTIR) spectra of NH2-GQDs (A–D), COOH-GQDs (E–H) and Green-GQDs (I–L).
Figure 2Toxicity of GQDs on U87 and cortical neurons after the treatment with GQDs. Cell viability normalized by control U87 untreated cells (A) and cortical neurons (B). Reactive oxygen species (ROS) production measured by fluorescence intensity of 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) for U87 (C) and cortical neurons (D) normalized by control cells.
Figure 3Effect of GQDs on secretion of cytokines, as reported in the relative legend, for U87 (A) and cortical neurons (B). Data are expressed as the mean normalized to the untreated control cells ± standard deviation. Line profile of DNA fragmentation for U87 and cortical neurons (C).
Figure 4Synergy of GQDs and doxorubicin (Dox). Normalized cell viability for U87 (A) and cortical primary neurons (B) after the treatment with GQDs and Dox separately. Isoboles’ graphs of Dox with NH2, COOH, and Green-GQDs, respectively, on U87, to determine the presence of synergistic effects (C–E). Synergy expressed as the ratio between the theoretical additive effect of GQDs with Dox and the measured effect (F). ** p < 0.01, one-way ANOVA, and Tukey post hoc test.
Figure 5Dox uptake inside U87 (A) and cortical primary neurons (B) after the pretreatment with GQDs at 250 µg/mL. Fluorescence intensity of Dox inside U87 cells (C) and inside cortical neurons (D). ** p < 0.01, one-way ANOVA and Tukey post hoc test.
Figure 6Membrane fluidity measured through generalized polarization (GP) of Laurdan emission for U87 (A) and cortical neurons (B). GP values measured for U87 (C) and cortical neurons (D). The -potential of GQDs (E). Correlation between -potential and GP for U87 (in green) and cortical neurons (in red) (F). ** p < 0.01, one-way ANOVA and Tukey post hoc test.
Scheme 1Synergistic mechanism between GQDs and Dox on U87. When Dox approaches cells, its uptake increases with the increase in membrane permeability. The amount of Dox uptake inside an untreated cell (A) is less than that of cells pretreated with COOH and Green-GQDs (B).